Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartman, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R.

http://www.ncbi.nlm.nih.gov/pubmed/29862437